 Joseph Rosenthal
Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bone Marrow Transplantation | 7 | 2024 | 298 | 0.860 |
Why?
| | Brain Injuries, Traumatic | 4 | 2016 | 462 | 0.770 |
Why?
| | Antibodies, Bacterial | 3 | 2016 | 148 | 0.630 |
Why?
| | Brain Ischemia | 4 | 2022 | 362 | 0.540 |
Why?
| | Bacterial Vaccines | 2 | 2016 | 63 | 0.530 |
Why?
| | Bacterial Outer Membrane Proteins | 2 | 2016 | 62 | 0.530 |
Why?
| | Antigens, Bacterial | 2 | 2016 | 126 | 0.520 |
Why?
| | Fatigue | 2 | 2016 | 367 | 0.490 |
Why?
| | Neurological Rehabilitation | 1 | 2016 | 16 | 0.480 |
Why?
| | Models, Neurological | 1 | 2016 | 253 | 0.410 |
Why?
| | Graft vs Host Disease | 4 | 2022 | 280 | 0.410 |
Why?
| | Vaccines, Virus-Like Particle | 1 | 2013 | 5 | 0.410 |
Why?
| | Th1 Cells | 1 | 2014 | 139 | 0.410 |
Why?
| | Stroke | 5 | 2026 | 1287 | 0.400 |
Why?
| | Drug Carriers | 1 | 2013 | 137 | 0.370 |
Why?
| | Escherichia coli | 3 | 2016 | 836 | 0.350 |
Why?
| | Seizures | 1 | 2016 | 491 | 0.350 |
Why?
| | Sports | 1 | 2014 | 216 | 0.340 |
Why?
| | Autonomic Dysreflexia | 1 | 2011 | 4 | 0.330 |
Why?
| | Blindness, Cortical | 1 | 2011 | 6 | 0.330 |
Why?
| | Quadriplegia | 1 | 2011 | 14 | 0.330 |
Why?
| | Population Surveillance | 1 | 2014 | 486 | 0.320 |
Why?
| | Athletes | 1 | 2014 | 431 | 0.310 |
Why?
| | Vaccines | 1 | 2013 | 389 | 0.280 |
Why?
| | Students | 1 | 2014 | 659 | 0.270 |
Why?
| | Hospitalization | 2 | 2026 | 2496 | 0.250 |
Why?
| | Nanoparticles | 1 | 2013 | 524 | 0.250 |
Why?
| | Athletic Injuries | 1 | 2014 | 576 | 0.250 |
Why?
| | Endovascular Procedures | 2 | 2022 | 395 | 0.240 |
Why?
| | Stroke Rehabilitation | 1 | 2026 | 44 | 0.230 |
Why?
| | Lymphoma | 2 | 2024 | 253 | 0.210 |
Why?
| | Occupational Therapy | 1 | 2026 | 110 | 0.200 |
Why?
| | Transplantation, Homologous | 3 | 2022 | 422 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2024 | 67 | 0.200 |
Why?
| | Maximum Tolerated Dose | 1 | 2024 | 217 | 0.200 |
Why?
| | Vaccines, Synthetic | 2 | 2014 | 137 | 0.200 |
Why?
| | Accidental Falls | 2 | 2016 | 231 | 0.190 |
Why?
| | Azacitidine | 1 | 2024 | 168 | 0.190 |
Why?
| | Peripheral Blood Stem Cell Transplantation | 1 | 2022 | 35 | 0.190 |
Why?
| | Mechanical Thrombolysis | 1 | 2022 | 5 | 0.180 |
Why?
| | Cell Membrane | 3 | 2014 | 711 | 0.180 |
Why?
| | Physical Therapy Modalities | 1 | 2026 | 346 | 0.180 |
Why?
| | Myelodysplastic Syndromes | 1 | 2024 | 170 | 0.180 |
Why?
| | Recovery of Function | 1 | 2026 | 724 | 0.170 |
Why?
| | Arterial Occlusive Diseases | 1 | 2022 | 90 | 0.170 |
Why?
| | Thrombectomy | 4 | 2022 | 79 | 0.170 |
Why?
| | Young Adult | 10 | 2024 | 14437 | 0.160 |
Why?
| | Neurologists | 1 | 2021 | 23 | 0.160 |
Why?
| | Restraint, Physical | 1 | 2021 | 76 | 0.160 |
Why?
| | Law Enforcement | 1 | 2021 | 53 | 0.160 |
Why?
| | Motor Cortex | 1 | 2020 | 65 | 0.150 |
Why?
| | Brain Injuries | 2 | 2015 | 508 | 0.150 |
Why?
| | Carotid Arteries | 1 | 2021 | 208 | 0.150 |
Why?
| | Adult | 15 | 2024 | 41405 | 0.150 |
Why?
| | Amyotrophic Lateral Sclerosis | 1 | 2020 | 96 | 0.150 |
Why?
| | Gene Expression | 2 | 2014 | 1481 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 2 | 2024 | 700 | 0.150 |
Why?
| | Female | 22 | 2026 | 80076 | 0.150 |
Why?
| | Patient Discharge | 1 | 2026 | 1002 | 0.140 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2022 | 703 | 0.140 |
Why?
| | Unrelated Donors | 1 | 2019 | 39 | 0.140 |
Why?
| | Male | 19 | 2026 | 73950 | 0.140 |
Why?
| | Physician's Role | 1 | 2021 | 225 | 0.140 |
Why?
| | Anemia, Aplastic | 1 | 2018 | 42 | 0.140 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1266 | 0.140 |
Why?
| | Cerebrovascular Circulation | 1 | 2021 | 293 | 0.140 |
Why?
| | Humans | 29 | 2026 | 147293 | 0.130 |
Why?
| | Adolescent | 10 | 2024 | 22825 | 0.130 |
Why?
| | Alanine | 2 | 2016 | 173 | 0.130 |
Why?
| | Time Factors | 5 | 2026 | 7173 | 0.130 |
Why?
| | Epilepsy, Post-Traumatic | 1 | 2016 | 6 | 0.120 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2016 | 21 | 0.120 |
Why?
| | Neisseria meningitidis, Serogroup B | 1 | 2016 | 15 | 0.120 |
Why?
| | Immunoglobulin Class Switching | 1 | 2016 | 21 | 0.120 |
Why?
| | Transport Vesicles | 1 | 2016 | 22 | 0.120 |
Why?
| | Sensation Disorders | 1 | 2016 | 40 | 0.120 |
Why?
| | Immunization | 2 | 2016 | 375 | 0.120 |
Why?
| | Threonine | 1 | 2016 | 44 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2022 | 3980 | 0.120 |
Why?
| | Bone Marrow | 3 | 2024 | 310 | 0.120 |
Why?
| | Craniotomy | 1 | 2016 | 84 | 0.120 |
Why?
| | Francisella tularensis | 1 | 2016 | 33 | 0.120 |
Why?
| | Tularemia | 1 | 2016 | 30 | 0.120 |
Why?
| | Polysaccharides | 1 | 2016 | 89 | 0.120 |
Why?
| | Leukemia | 1 | 2018 | 247 | 0.120 |
Why?
| | Remission Induction | 1 | 2016 | 310 | 0.110 |
Why?
| | Valine | 1 | 2016 | 83 | 0.110 |
Why?
| | International Classification of Diseases | 1 | 2016 | 151 | 0.110 |
Why?
| | Aged | 9 | 2026 | 26514 | 0.110 |
Why?
| | Blood Transfusion | 1 | 2018 | 412 | 0.110 |
Why?
| | Community Participation | 1 | 2016 | 128 | 0.110 |
Why?
| | Recombinant Fusion Proteins | 2 | 2014 | 669 | 0.110 |
Why?
| | Psychomotor Agitation | 1 | 2015 | 69 | 0.110 |
Why?
| | Hemolysin Proteins | 1 | 2014 | 36 | 0.110 |
Why?
| | Middle Aged | 8 | 2026 | 36821 | 0.110 |
Why?
| | Geriatric Assessment | 1 | 2016 | 240 | 0.110 |
Why?
| | Anemia, Sickle Cell | 1 | 2019 | 322 | 0.110 |
Why?
| | Vaccines, Subunit | 1 | 2014 | 53 | 0.100 |
Why?
| | Genes, Synthetic | 1 | 1994 | 13 | 0.100 |
Why?
| | Bungarotoxins | 1 | 1994 | 45 | 0.100 |
Why?
| | Inpatients | 2 | 2015 | 556 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 2001 | 0.100 |
Why?
| | Probiotics | 1 | 2014 | 61 | 0.100 |
Why?
| | Epitopes | 1 | 2016 | 475 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2016 | 3027 | 0.100 |
Why?
| | Epidemiologic Studies | 1 | 2014 | 72 | 0.100 |
Why?
| | Triage | 1 | 2016 | 250 | 0.100 |
Why?
| | Long-Term Potentiation | 1 | 2016 | 206 | 0.100 |
Why?
| | Craniocerebral Trauma | 1 | 2016 | 180 | 0.100 |
Why?
| | Immunity, Humoral | 1 | 2014 | 119 | 0.100 |
Why?
| | Biomimetics | 1 | 2013 | 41 | 0.100 |
Why?
| | Species Specificity | 1 | 2014 | 547 | 0.100 |
Why?
| | Postural Balance | 1 | 2016 | 254 | 0.100 |
Why?
| | Amyloid beta-Peptides | 1 | 2016 | 251 | 0.100 |
Why?
| | Immunity, Cellular | 1 | 2014 | 280 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5476 | 0.090 |
Why?
| | Escherichia coli Proteins | 1 | 2014 | 201 | 0.090 |
Why?
| | Sleep Wake Disorders | 1 | 2016 | 315 | 0.090 |
Why?
| | Adjuvants, Immunologic | 1 | 2013 | 245 | 0.090 |
Why?
| | Risk Factors | 5 | 2018 | 11017 | 0.090 |
Why?
| | Peptide Fragments | 1 | 2016 | 698 | 0.090 |
Why?
| | Treatment Outcome | 6 | 2024 | 11947 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2142 | 0.080 |
Why?
| | Schools | 1 | 2014 | 453 | 0.080 |
Why?
| | Aged, 80 and over | 5 | 2024 | 8430 | 0.080 |
Why?
| | Thrombolytic Therapy | 2 | 2022 | 165 | 0.080 |
Why?
| | Transplantation, Autologous | 2 | 2024 | 307 | 0.080 |
Why?
| | Biocompatible Materials | 1 | 2013 | 432 | 0.070 |
Why?
| | Depression | 2 | 2016 | 1599 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 251 | 0.070 |
Why?
| | Prospective Studies | 5 | 2021 | 8164 | 0.070 |
Why?
| | Radiography | 1 | 2011 | 862 | 0.070 |
Why?
| | Bacteria | 1 | 2014 | 769 | 0.070 |
Why?
| | Infant | 5 | 2022 | 10194 | 0.070 |
Why?
| | Anxiety | 1 | 2015 | 1149 | 0.070 |
Why?
| | Prognosis | 1 | 2016 | 4383 | 0.060 |
Why?
| | Canada | 2 | 2021 | 435 | 0.060 |
Why?
| | Child, Preschool | 5 | 2022 | 12016 | 0.060 |
Why?
| | Emergency Service, Hospital | 2 | 2016 | 2416 | 0.060 |
Why?
| | Incidence | 3 | 2018 | 2954 | 0.060 |
Why?
| | United States | 4 | 2021 | 16313 | 0.060 |
Why?
| | Child | 6 | 2024 | 22979 | 0.060 |
Why?
| | Brain Concussion | 1 | 2014 | 661 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2026 | 17560 | 0.060 |
Why?
| | Mice | 4 | 2016 | 18491 | 0.060 |
Why?
| | Rehabilitation Centers | 2 | 2015 | 39 | 0.060 |
Why?
| | Carbolines | 1 | 2024 | 35 | 0.050 |
Why?
| | Heterocyclic Compounds, 4 or More Rings | 1 | 2024 | 24 | 0.050 |
Why?
| | Animals | 6 | 2016 | 38410 | 0.050 |
Why?
| | Survival Rate | 2 | 2019 | 2110 | 0.050 |
Why?
| | Protein Folding | 2 | 2016 | 280 | 0.050 |
Why?
| | Morbidity | 1 | 2024 | 323 | 0.050 |
Why?
| | Infant, Newborn | 3 | 2018 | 6543 | 0.050 |
Why?
| | Age Factors | 2 | 2021 | 3372 | 0.040 |
Why?
| | Reperfusion | 1 | 2021 | 54 | 0.040 |
Why?
| | Neck | 1 | 2021 | 109 | 0.040 |
Why?
| | Cerebral Hemorrhage | 1 | 2021 | 125 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2021 | 248 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2022 | 303 | 0.040 |
Why?
| | Histocompatibility Testing | 1 | 2019 | 123 | 0.040 |
Why?
| | Transfusion Reaction | 1 | 2018 | 61 | 0.030 |
Why?
| | Brain | 1 | 2011 | 3009 | 0.030 |
Why?
| | Allografts | 1 | 2019 | 152 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 1166 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2019 | 779 | 0.030 |
Why?
| | Cohort Studies | 2 | 2018 | 6099 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 568 | 0.030 |
Why?
| | O Antigens | 1 | 2016 | 8 | 0.030 |
Why?
| | Antigen-Antibody Reactions | 1 | 2016 | 49 | 0.030 |
Why?
| | Hematologic Neoplasms | 1 | 2018 | 169 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2018 | 177 | 0.030 |
Why?
| | Microtomy | 1 | 2016 | 4 | 0.030 |
Why?
| | Mortality | 1 | 2018 | 382 | 0.030 |
Why?
| | Acute Disease | 1 | 2019 | 1049 | 0.030 |
Why?
| | Glycosylation | 1 | 2016 | 176 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2016 | 430 | 0.030 |
Why?
| | Cause of Death | 1 | 2018 | 475 | 0.030 |
Why?
| | Colorado | 1 | 2026 | 4591 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2018 | 975 | 0.030 |
Why?
| | Trauma Severity Indices | 1 | 2015 | 117 | 0.030 |
Why?
| | Protein Stability | 1 | 2016 | 176 | 0.030 |
Why?
| | Microscopy, Atomic Force | 1 | 2016 | 129 | 0.030 |
Why?
| | Protein Aggregates | 1 | 2016 | 86 | 0.030 |
Why?
| | Hydrophobic and Hydrophilic Interactions | 1 | 2016 | 194 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 303 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2016 | 205 | 0.030 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 299 | 0.030 |
Why?
| | Chromatography, DEAE-Cellulose | 1 | 1994 | 10 | 0.030 |
Why?
| | Electric Organ | 1 | 1994 | 8 | 0.030 |
Why?
| | Torpedo | 1 | 1994 | 10 | 0.030 |
Why?
| | Survivors | 1 | 2018 | 528 | 0.030 |
Why?
| | Snakes | 1 | 1994 | 19 | 0.030 |
Why?
| | Factor Xa | 1 | 1994 | 36 | 0.030 |
Why?
| | Bioengineering | 1 | 2014 | 20 | 0.030 |
Why?
| | Aspartic Acid | 1 | 1994 | 88 | 0.030 |
Why?
| | Oligodeoxyribonucleotides | 1 | 1994 | 141 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 1994 | 377 | 0.020 |
Why?
| | Cloning, Molecular | 1 | 1994 | 539 | 0.020 |
Why?
| | Protein Structure, Secondary | 1 | 1994 | 372 | 0.020 |
Why?
| | Point Mutation | 1 | 1994 | 245 | 0.020 |
Why?
| | Trauma Centers | 1 | 2016 | 468 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2015 | 602 | 0.020 |
Why?
| | Linear Models | 1 | 2015 | 852 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 425 | 0.020 |
Why?
| | Kinetics | 1 | 2016 | 1569 | 0.020 |
Why?
| | Sex Factors | 1 | 2018 | 2136 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 1994 | 1371 | 0.020 |
Why?
| | Pilot Projects | 1 | 2016 | 1912 | 0.020 |
Why?
| | Base Sequence | 1 | 1994 | 2175 | 0.020 |
Why?
| | Amino Acid Sequence | 1 | 1994 | 2134 | 0.020 |
Why?
| | Hippocampus | 1 | 2016 | 989 | 0.020 |
Why?
| | Protein Binding | 1 | 2016 | 2249 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 1994 | 2886 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2014 | 489 | 0.020 |
Why?
| | Cognitive Dysfunction | 1 | 2015 | 479 | 0.020 |
Why?
| | Models, Molecular | 1 | 1994 | 1606 | 0.020 |
Why?
| | Prevalence | 1 | 2015 | 2889 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1598 | 0.020 |
Why?
| | Vaccination | 1 | 2016 | 1443 | 0.020 |
Why?
| | Risk Assessment | 1 | 2016 | 3784 | 0.020 |
Why?
| | Mutation | 1 | 2016 | 4130 | 0.010 |
Why?
|
|
Rosenthal's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|